Roche Tecentriq Colon Cancer Milestone: FDA Approves Tecentriq and Tecentriq Hybreza With Chemotherapy for Stage III dMMR Disease

Roche Tecentriq colon cancer treatment options expanded on 9 October 2026, when Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). Both are approved in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a tumour type characterised by high mutation rates.

The decision is the twelfth US indication for Tecentriq. According to Roche, it also creates the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, which the company says positions Tecentriq as a new post-surgery standard of care. The announcement was issued from Basel, Switzerland, by Roche Global Media Relations.

Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development, described the approval as a new adjuvant option for people at high risk of recurrence. He said Tecentriq combined with chemotherapy has the potential to become the new standard of care. That is a forward-looking statement from Roche, not an FDA finding. For readers tracking Roche Tecentriq colon cancer developments, the framing matters because the regimen is the first immunotherapy-based option approved for this setting.

Roche Tecentriq Colon Cancer Approval: What the FDA Cleared and for Whom

The FDA approval covers two products: Tecentriq and Tecentriq Hybreza. Roche describes Tecentriq as the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations. The release does not state a US availability date, a list price or full prescribing information, so those items are not disclosed in the source.

Learn More

Eli Lilly Secures FDA Jaypirca Approval for Pirtobrutinib in Previously Untreated CLL/SLL

Eligibility depends on biomarker status. The Roche Tecentriq colon cancer data come from patients whose stage III dMMR status was determined by an immunohistochemistry test, such as the VENTANA MMR RxDx Panel. Roche says approximately 15% of colon cancer patients present with dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a higher mutation rate and potential to respond to immunotherapy.

Tecentriq is a monoclonal antibody that binds PD-L1, a protein expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, the medicine may enable re-activation of T cells, although Roche notes it may also affect normal cells. The company states that Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer.

Roche Tecentriq Colon Cancer Evidence: ATOMIC Phase III Trial Results

The approval is based on the phase III ATOMIC study (A021502), registered as NCT02912559 and recently published in The New England Journal of Medicine. ATOMIC is randomised, open-label and multicentre, and it enrolled 712 patients with stage III dMMR colon cancer. The Roche Tecentriq colon cancer evidence comes from a trial that Roche calls landmark.

Participants were randomised 1:1. One arm received mFOLFOX6 (a combination of folinic acid, fluorouracil and oxaliplatin) plus Tecentriq for 12 cycles, or six months, followed by Tecentriq monotherapy for 13 cycles, an additional six months. The comparator arm received mFOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS).

Adding Tecentriq to mFOLFOX6 reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone. At 36 months, DFS was 86% with Tecentriq plus mFOLFOX6 and 76% with mFOLFOX6 alone. Roche reports a safety profile consistent with previous studies of Tecentriq and mFOLFOX6. Hazard ratios, confidence intervals, overall survival and adverse-event rates are not disclosed in the release. In the Roche Tecentriq colon cancer dataset, the 10-percentage-point DFS gap at three years is the headline figure.

Learn More

Pfizer TUKYSA FDA Approval: Chemotherapy-Free Front-Line Maintenance Now Available for HER2+ Metastatic Breast Cancer

The US study was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the Alliance for Clinical Trials in Oncology with participation from other NCI-funded National Clinical Trials Network groups. Genentech, a member of the Roche Group, supported the trial through a Cooperative Research and Development Agreement between NCI and Genentech. Frank A. Sinicrope, MD, of the Mayo Clinic, led the trial globally. German participation was enabled through cooperation between the Alliance and AIO-Studien-gGmbH under the national leadership of Prof. Dr. Anke Reinacher-Schick of Ruhr-Universität Bochum.

Roche Tecentriq Colon Cancer Burden: Why Stage III dMMR Disease Matters

Colon cancer remains one of the world’s most common and deadliest tumours, according to Roche, which cites the World Health Organization. Over one million people are diagnosed globally each year, and nearly 25% of all colon cancers are diagnosed at stage III. Despite surgery and chemotherapy, nearly 30% of stage III patients experience recurrence within five years, which the release’s headline bullet describes as almost one in three. These figures frame the unmet need behind a Roche Tecentriq colon cancer option in the adjuvant setting.

Frank A. Sinicrope, US Principal Investigator for the Alliance ATOMIC trial, said the adjuvant standard of care for stage III colon cancer has until now not differed by mismatch repair status. He called the result a therapeutic advance that targets the specific biology of dMMR stage III disease after surgical resection, and he described the regimen as practice-changing.

Roche supports its disease-burden claims with references including a 2026 New England Journal of Medicine report on atezolizumab plus FOLFOX, recurrence analyses in Annals of Oncology and JAMA Oncology, WHO cancer data and a 2010 Gastroenterology paper on microsatellite instability. Readers evaluating the Roche Tecentriq colon cancer announcement can check these sources directly.

Roche Tecentriq Colon Cancer Outlook: Regulatory Next Steps and Company Context

Roche says it is pursuing further regulatory filings for Tecentriq, including with the European Medicines Agency, to bring this immunotherapy-based adjuvant option to patients with dMMR colon cancer worldwide as soon as possible. This is a forward-looking statement. Filing dates, review timelines and approval outcomes outside the US are not disclosed. Any ex-US Roche Tecentriq colon cancer decision depends on those reviews.

Roche describes its oncology commitment as spanning more than 60 years, with a focus on breast, lung and blood cancers alongside other areas of unmet need. Its pipeline spans small molecules, antibodies, next-generation antibody-drug conjugates and allogeneic CAR T-cell therapies.

Roche was founded in Basel, Switzerland, in 1896 and serves people in over 150 countries across its Diagnostics and Pharmaceuticals divisions. Genentech in the United States is a fully owned subsidiary, and Roche is the majority shareholder in Chugai Pharmaceutical. Further company information is available on the Roche media releases page and in related coverage.

Table 1: Approval Snapshot

Table 2: ATOMIC Trial Design

Table 3: ATOMIC Efficacy and Safety

Table 4: Disease Context Cited by Roche